Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...
MDNA11 is a next-generation IL-2 superkine designed to selectively stimulate effector immune cells (CD8 + T cells and NK cells) by enhancing affinity for IL-2Rβ (CD122) while avoiding IL-2Rα (CD25), ...
ImmunityBio’s lead product, Anktiva, is central to its innovative cancer treatment strategy. Anktiva is an interleukin-15 (IL ...
According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible for ...
Patients with melanoma brain metastases had better survival if they received radiotherapy (RT) followed by immunotherapy ...
Their study, published in Oncogene, explores how increased methylmalonic acid impairs the activation and effector functions of CD8+ T cells, immune cells that play a vital role in fighting cancer.
Zacks Small Cap Research on MSN4 天
FBLG: On Target to Initiate Phase 1/2 Trial in 2025…
FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On Track to Initiate Phase 1/2 Trial in Diabetic Foot Ulcers FibroBiologics, Inc. (NASDAQ:FBLG) is on track to initiate a Phase 1/2 trial of ...
Immunotherapy, which enhances the immune system's T cell response to eliminate cancer cells, has emerged as a key approach in ...
Professor Heung Kyu Lee, KAIST Department of Biological Sciences, and Dr. Keun Bon Ku >Immunotherapy, which enhances the ...
In the oral presentation, the investigators reported ongoing improved survival compared to historical controls, with 3 out of ...
撰稿 | 郑诗蔚   责编 | 周叶斌近年来,靶向CD19的CAR T细胞疗法在治疗儿童和青少年复发或难治性急性淋巴细胞白血病(ALL)方面卓有成效,但约一半的患者在CAR ...
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...